Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of$ 8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer’s disease – - Companies expect transaction to close in third quarter of 2025 - WATE ...